Roy Gulick
机构: Professor of Medicine, Weill Cornell
每年引用次数
引用次数
引用: 25,736
H-指数: 67
I10-指数 : 168
出版物: 298
Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank
Shanti Narayanasamy , Lesley H Curtis , Adrian F Hernandez , Christopher W Woods
Clinical Infectious Diseases 77 ( 12) 1635 -1643
2
2023
Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069/ACTG A5305)
Roy M Gulick , Timothy J Wilkin , Ying Q Chen , Raphael J Landovitz
The Journal of infectious diseases 215 ( 2) 238 -246
59
2017
When to Start Antiretroviral Therapy
Timothy J Wilkin , Roy M Gulick , Kenneth H Mayer
Clinical Infectious Diseases 47 ( 12) 1580 -1586
30
2008
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305
Todd T Brown , Krista Yuhas , Kenneth H Mayer , Raphael J Landovitz
Journal of Antimicrobial Chemotherapy 77 ( 2) 500 -506
3
2022
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)
Kenneth H Mayer , Krista Yuhas , K Rivet Amico , Timothy Wilkin
AIDS and Behavior 26 ( 12) 4107 -4114
2
2022
Phase 2 safety and tolerability study of maraviroc-containing regimens to prevent HIV infection in women (HPTN 069/ACTG A5305): a randomized trial
Roy M Gulick , Timothy J Wilkin , Ying Q Chen , Raphael J Landovitz
Annals of internal medicine 167 ( 6) 384 -384
1
2017
Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidates
Jeremy Sugarman , Brian W Weir , Chen Dun , Roy M Gulick
AIDS care 1 -7
2024
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria
Jesse Fajnzylber , Radwa Sharaf , John N Hutchinson , Evgenia Aga
Aids 35 ( 13) 2225 -2227
12
2021
Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment FailureA Randomized Trial
Scott M Hammer , Florin Vaida , Kara K Bennett , Mary K Holohan
JAMA 288 ( 2) 169 -180
166
2002
Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients
Constance A Benson , Steven G Deeks , Scott C Brun , Roy M Gulick
The Journal of Infectious Diseases 185 ( 5) 599 -607
127
2002
Pharmacogenomics of Hepatic Transaminase Elevation following Initiation of Antiretroviral Therapy: 359
Fausta A Difah , Daniel H Johnson , Paul Leger , Eric S Daar
Hepatology 58 383A -383A
2013
Pharmacogenomics of Hepatic Transaminase Elevation following Initiation of Antiretroviral Therapy
Fausta A Ditah , Daniel H Johnson , Paul Leger , Eric S Daar
HEPATOLOGY 58 383A -383A
2013
Changes in HIV-1 Subtypes B and C Genital Tract RNA in Women and Men After Initiation of Antiretroviral Therapy
Susan A Fiscus , Susan Cu-Uvin , Abel Tilahun Eshete , Michael D Hughes
Clinical Infectious Diseases 57 ( 2) 290 -297
18
2013
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection
Dennis C Copertino Jr , Bruno C Casado Lima , Rodrigo RR Duarte , Timothy R Powell
Journal of Biomolecular Structure and Dynamics 40 ( 16) 7367 -7380
22
2022
A Conversation Among the IAS–USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care
Constance A Benson , Judith S Currier , Carlos Del Rio , Joel E Gallant
Topics in antiviral medicine 24 ( 4) 142 -142
3
2016
MB, FRCP, FRCPE
Thierry Calandra , Nathan Clumeck , Jeremy Day , FRS Jeremy Farrar
Developing treatment guidelines during a pandemic health crisis: lessons learned from COVID-19
Safia Kuriakose , Kanal Singh , Alice K Pau , Eric Daar
Annals of internal medicine 174 ( 8) 1151 -1158
18
2021
COURSE FACULTY
Roy M Gulick , Jessica E Justman , Susan L Koletar , Thomas C Quinn
AN ADVANCED CME COURSE IN HIV PATHOGENESIS, ANTIRETROVIRALS, AND OTHER SELECTED ISSUES IN HIV DISEASE MANAGEMENT 4 -4
2010
Selecting treatments during an infectious disease pandemic: chasing the evidence
Marshall J Glesby , Roy M Gulick
Annals of Internal Medicine 174 ( 10) 1464 -1465
6
2021
HIV: closing the mortality gap
Marshall J Glesby , Roy M Gulick
Annals of Internal Medicine 174 ( 9) 1311 -1312
1
2021